Author:
Rajesh Reddy P.,Musunuri Sivanadh,Rama Sekhara Reddy D.,Chittala V. Subrahmanyam,Murthy P V. N. S.,Krishnamohan K.
Abstract
Abstract
Background
Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specifil phophodiesterase type 5 (PDE5). Sildenafil enhances the effect of nitric oxide by inhibiting phosphodiesterase type 5, which is responsible for the degradation of cGMP in the corpus cavernosum. The possible genotoxic impurities of sildenafil were synthesized, i.e., sildenafil sulfonyl methyl ester, sildenafil sulfonyl ethyl ester, and sildenafil sulfonyl isopropyl ester. The present work describes the synthesis and characterization of these sulfonyl ester compounds related to sildenafil.
Results
All the synthesized sildenafil sulfonyl esters have proved to be beneficial for the pharmaceutical industry in view of the regulatory importance.
Conclusion
A simple, efficient, and repeatable method was developed for the preparation of sildenafil sulfonyl esters in view of the regulatory importance of the potential genotoxic impurities in the active pharmaceutical ingredient. A detailed study of various impurities in sildenafil was conducted. Different process-related sulfonyl esters in sildenafil were identified, synthesized, and characterized by using various spectroscopic techniques like liquid chromatography-mass spectrometry (LCMS), mass, 1H NMR, and FT-IR. These efforts to synthesize and characterize them effectively have proved to be beneficial.
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. International Conference on Harmonization (ICH) guidelines Q3A (R) impurities in New Drug Substances (2002) ICH guidelines, Geneva
2. International Conference on Harmonization (ICH) guidelines Q2B validation of analytical Procedure (1996) Methodology, Geneva
3. M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk; ICH guidelines: 2018
4. Raman NVSSS, Prasad AVSS, Ratnakar Reddy K (2011) Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical perspective. J Pharm Biomed Anal 55:662–667. https://doi.org/10.1016/j.jpba.2010.11.039
5. European medicines agency. Guideline on the specification limits for residues of metal catalysts or metal reagents, Doc. Ref. EMEA/CHMP/SWP/4446/2000, European Medicines Agency, 2008.